MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Opexa Therapeutics Company Profile (NASDAQ:OPXA)

Consensus Ratings for Opexa Therapeutics (NASDAQ:OPXA) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (175.00% upside)

Analysts' Ratings History for Opexa Therapeutics (NASDAQ:OPXA)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016AegisReiterated RatingBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Chardan CapitalInitiated CoverageBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Opexa Therapeutics (NASDAQ:OPXA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q116($0.35)($0.31)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.50)($2.05)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($2.48)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.08)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.15)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2015($0.14)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.13)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2012Q312($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Opexa Therapeutics (NASDAQ:OPXA)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Opexa Therapeutics (NASDAQ:OPXA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Opexa Therapeutics (NASDAQ:OPXA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Opexa Therapeutics (NASDAQ:OPXA)
DateHeadline
06/21/16 10:03 AMInvestors Are Watching: Globalstar Inc. (NYSEMKT:GSAT), Opexa Therapeutics (NASDAQ:OPXA), Advanced Micro ... - KC Register
06/20/16 07:16 AMOpexa Therapeutics, Inc. (OPXA) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 09:53 AMManufacturing Industry Top Gainers, Biggest Losers Summary
06/11/16 05:50 PMEarnings Analysis to Watch: Banco Santander (NYSE:BSBR), Opexa Therapeutics, Inc. (NASDAQ:OPXA) - Beacon Chronicle
06/03/16 08:33 AMStrong Sell Calls Count For Opexa Therapeutics, Inc. (NASDAQ:OPXA) At 0 - Investor Newswire - Strong Sell Calls Count For Opexa Therapeutics, Inc. (NASDAQ:OPXA) At 0Investor NewswireOpexa Therapeutics, Inc. (NASDAQ:OPXA) has a total of 2 Strong Buy calls and 0 Strong Sell advises as of 2016-06-01. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2, it is ...and more »
05/28/16 01:27 PMAnalyst Recommendations on These Stocks: Computer Sciences (CSC), Opexa Therapeutics (OPXA) - Beacon Chronicle - Analyst Recommendations on These Stocks: Computer Sciences (CSC), Opexa Therapeutics (OPXA)Beacon ChronicleLast Trade: The Company closed its last session at $ 50.66yesterday with the gain of 42.10%. The market capitalization of the company is $ 7.12Billion, with the average Volume of $ 1.12Million. The stock currently has its 52-Week High range of $ 50 ...and more »
05/26/16 01:31 PMU.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.82% - The top performers on the NASDAQ Composite were Innocoll AG (NASDAQ:INNL) which rose 47.82% to 10.51, Opexa Therapeutics Inc (NASDAQ:OPXA) which was up 27.52% to settle at 3.290 and Sarepta Therapeutics Inc (NASDAQ:SRPT) which gained 26.63% to close at 23.350.
05/26/16 01:31 PMVery Green Follow-Through Session - On the downside, no stocks were down as much as a point on our main board. Checking the TheTechTrader.com percent-gain leaderboard, Opexa Therapeutics, Inc. (OPXA), on earnings, spiked to 4.29 this morning, before pulling back to 3.29, up 71 cents ...
05/26/16 01:31 PMOpexa Therapeutics Inc. (OPXA) Has Surged To Nearly A 6-Month High - Opexa Therapeutics Inc. (OPXA) has been rising steadily since the open of trade Wednesday and is now up 1.31 at $3.89 on the highest volume in 6 months. Opexa Therapeutics is adding to its gains from the previous session and has broken out to nearly a 6 ...
05/25/16 01:34 PMHealthcare Stocks to Lookout: Opexa Therapeutics Inc (NASDAQ:OPXA), Carbylan Therapeutics Inc (NASDAQ:CBYL ... - The Point Review - Healthcare Stocks to Lookout: Opexa Therapeutics Inc (NASDAQ:OPXA), Carbylan Therapeutics Inc (NASDAQ:CBYL ...The Point ReviewShares of Opexa Therapeutics Inc (NASDAQ:OPXA) flew 28.99% to $3.33 at 12:04 PM EDT. The stock attained the volume of 3.72 Million shares recently versus average trading volume of 24,389 shares. If we take a look on its volatility, 8.55 percent was ...Opexa Therapeutics Inc (NASDAQ:OPXA)'s Company Shares Increased 12.17% After High VolatilityWall Street Hints and Newsall 2 news articles »
05/24/16 02:01 PMNext Weeks Broker Price Targets For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Next Weeks Broker Price Targets For Opexa Therapeutics, Inc. (OPXA)Share Trading NewsOpexa Therapeutics, Inc. has a 50 day moving average of 2.40 and a 200 day moving average of 2.51. The stock's market capitalization is 14.95M, it has a 52-week low of 1.69 and a 52-week high of 5.84. The share price of the company (OPXA) was up ...and more »
05/21/16 01:21 PMRevenue Update on Opexa Therapeutics Inc(NASDAQ:OPXA) - Trade Calls - Revenue Update on Opexa Therapeutics Inc(NASDAQ:OPXA)Trade CallsOpexa Therapeutics Inc(NASDAQ:OPXA) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 12, 2016. Company reported revenue of $726.29K. Analysts estimated a revenue of $400.00K. Earnings ...Opexa Therapeutics Incorporated (NASDAQ:OPXA) Short Interest Decreased By 4.44%Franklin Independentall 2 news articles »
05/18/16 03:07 PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/18/16 02:03 PMMorning Alert: Comcast Corporation (NASDAQ:CMCSA), Opexa Therapeutics, Inc. (NASDAQ:OPXA), NuVasive, Inc ... - KC Register - Morning Alert: Comcast Corporation (NASDAQ:CMCSA), Opexa Therapeutics, Inc. (NASDAQ:OPXA), NuVasive, Inc ...KC RegisterOpexa Therapeutics, Inc. (NASDAQ:OPXA) reported financial results for the quarter ended March 31, 2016. Net loss reported for the quarter ended March 31, 2016 was $2,160,394, or $.31 per share (basic and diluted), compared with a net loss of $3,350,880 ...
05/18/16 12:48 PMOpexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/14/16 07:36 AMBroker Roundup For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Broker Roundup For Opexa Therapeutics, Inc. (OPXA)Share Trading News03/24/2014 – Brinson Patrick began new coverage on Opexa Therapeutics, Inc. giving the company a “buy” rating. The share price of Opexa Therapeutics, Inc. (OPXA) was down -9.62% during the last trading session, with a day high of 2.38. 53997 shares ...Opexa Therapeutics' (OPXA) CEO Neil Warma on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaOpexa Therapeutics (OPXA) Tops Q1 EPS by 4cStreetInsider.comOpexa Therapeutics Inc.: Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate ...The Wall Street Transcriptall 3 news articles »
05/13/16 08:02 AMOpexa Therapeutics' (OPXA) CEO Neil Warma on Q1 2016 Results - Earnings Call Transcript - Seeking Alpha - Opexa Therapeutics' (OPXA) CEO Neil Warma on Q1 2016 Results - Earnings Call TranscriptSeeking AlphaGood afternoon, everyone, and welcome to the Opexa Therapeutics first quarter conference call. During today's call, members of our Senior Management team will review Opexa's financial performance and business highlights for the quarter ending March 31, ...Opexa Therapeutics (OPXA) Tops Q1 EPS by 4cStreetInsider.comOpexa Therapeutics Inc.: Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate ...The Wall Street Transcriptall 3 news articles »
05/12/16 04:27 PMOpexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - Conference Call Scheduled Today at 4:30 PM ET THE WOODLANDS, TX -- (Marketwired) -- 05/12/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies ...
05/12/16 03:10 PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/12/16 03:09 PMOPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/12/16 06:07 AMQ1 2016 Opexa Therapeutics Inc Earnings Release - After Market Close -
05/10/16 08:18 AMOpexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results - [at noodls] - THE WOODLANDS, TX -- (Marketwired) -- 05/10/16 -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) ...
05/07/16 07:21 AMLatest Analyst Ratings For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Latest Analyst Ratings For Opexa Therapeutics, Inc. (OPXA)Share Trading NewsOpexa Therapeutics, Inc. has a 50 day moving average of 2.41 and a 200 day moving average of 2.58. The stock's market capitalization is 16.27M, it has a 52-week low of 1.69 and a 52-week high of 5.84. The share price of the company (OPXA) was up ...
04/27/16 09:15 AMOpexa Therapeutics, Inc. (OPXA) Analyst Review - Risers & Fallers - Opexa Therapeutics, Inc. (OPXA) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Opexa Therapeutics, Inc. (OPXA). According to the latest broker reports outstanding on Wednesday 27th of April, 0 analysts have a rating of “strong buy”, 0 analysts ...
04/27/16 07:30 AMOpexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact - [Marketwired] - Opexa Therapeutics, Inc. , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including for multiple sclerosis and neuromyelitis optica , today announced that ...
04/25/16 08:31 AMAfter Last Week What Do Analysts Think Of Opexa Therapeutics, Inc. (OPXA) - Share Trading News - After Last Week What Do Analysts Think Of Opexa Therapeutics, Inc. (OPXA)Share Trading News03/24/2014 – Brinson Patrick began new coverage on Opexa Therapeutics, Inc. giving the company a “buy” rating. The share price of Opexa Therapeutics, Inc. (OPXA) was up +0.00% during the last trading session, with a day high of 2.49. 20182 shares were ...How Many Opexa Therapeutics Inc (NASDAQ:OPXA)'s Analysts Are Bearish?Franklin Independentall 2 news articles »
04/23/16 08:06 AMOpexa Therapeutics Incorporated (NASDAQ:OPXA) Short Interest Decreased By 3.35% - The Post - Opexa Therapeutics Incorporated (NASDAQ:OPXA) Short Interest Decreased By 3.35%The PostThe short interest to Opexa Therapeutics Incorporated's float is 3.29%. The stock decreased 1.64% or $0.04 on April 22, hitting $2.4. About 20,182 shares traded hands. Opexa Therapeutics Inc (NASDAQ:OPXA) has declined 37.50% since September 16, ...
04/22/16 08:50 AMBroker Changes For Opexa Therapeutics, Inc. (OPXA) - Risers & Fallers - Broker Changes For Opexa Therapeutics, Inc. (OPXA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Opexa Therapeutics, Inc. (OPXA). The latest broker reports which are currently outstanding on Friday 22nd of April state 0 analysts have a rating of “strong buy”, 0 ...
04/21/16 08:53 AMBroker Outlook For Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Broker Outlook For Opexa Therapeutics, Inc. (OPXA)Share Trading NewsOpexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica ...
04/20/16 09:15 AMOpexa Therapeutics, Inc. (OPXA) Updated Broker Price Targets - Share Trading News - Opexa Therapeutics, Inc. (OPXA) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Opexa Therapeutics, Inc. (OPXA). The latest reports which are currently in issue on Wednesday 20th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...
04/19/16 09:13 AMCan Shares Of Opexa Therapeutics, Inc. (NASDAQ:OPXA) Hit $24.48? - Investor Newswire - Can Shares Of Opexa Therapeutics, Inc. (NASDAQ:OPXA) Hit $24.48?Investor NewswireThe Buy recommendations for Opexa Therapeutics, Inc. (NASDAQ:OPXA) stock is 1, sell recommendations at 0 and hold recommendations count at 0. It boasts a total of 2 Strong Buy calls and 0 Strong Sell calls as of 2016-04-18. One month ago, the strong ...and more »
04/17/16 07:20 AMAre Analysts Bullish Opexa Therapeutics Inc (NASDAQ:OPXA) After Last Week? - Business Standard Tribune - Are Analysts Bullish Opexa Therapeutics Inc (NASDAQ:OPXA) After Last Week?Business Standard TribuneOut of 5 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Opexa Therapeutics was the topic in 2 analyst reports since September 28, 2015 according to StockzIntelligence Inc ...
04/14/16 01:11 PMOpexa Therapeutics Incorporated (NASDAQ:OPXA) Sellers Covered 16% of Their Shorts - RiversideGazette.com - Opexa Therapeutics Incorporated (NASDAQ:OPXA) Sellers Covered 16% of Their ShortsRiversideGazette.comThe short interest to Opexa Therapeutics Incorporated's float is 3.41%. The stock increased 1.19% or $0.03 on April 13, hitting $2.55. About 26,845 shares traded hands. Opexa Therapeutics Inc (NASDAQ:OPXA) has declined 30.40% since September 4, 2015 ...and more »
04/12/16 11:47 AMBroker Outlook For The Week Ahead Opexa Therapeutics, Inc. (OPXA) - Share Trading News - Broker Outlook For The Week Ahead Opexa Therapeutics, Inc. (OPXA)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Opexa Therapeutics, Inc. (OPXA). The most recent broker reports which have been released note that 0 analysts have a ...
04/11/16 05:51 PMEdited Transcript of OPXA earnings conference call or presentation 15-Mar-16 8:30pm GMT -
04/05/16 01:19 PMCurrent Price Targets For Opexa Therapeutics, Inc. (OPXA) - Risers & Fallers - Current Price Targets For Opexa Therapeutics, Inc. (OPXA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Opexa Therapeutics, Inc. (OPXA). The latest broker reports which are currently outstanding on Tuesday 5th of April state 0 analysts have a rating of “strong buy”, 4 ...
04/03/16 01:07 PMOpexa Therapeutics, Inc. (OPXA) Broker Price Targets For The Coming Week - Share Trading News - Opexa Therapeutics, Inc. (OPXA) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Opexa Therapeutics, Inc. (OPXA). The latest reports which are currently in issue on Sunday 3rd of April state 0 analysts have a rating of “strong buy”, 4 analysts “buy ...
04/01/16 01:39 PMHow Analysts Rated Opexa Therapeutics Inc (NASDAQ:OPXA) Last Week? - Stock Caller - How Analysts Rated Opexa Therapeutics Inc (NASDAQ:OPXA) Last Week?Stock CallerOut of 5 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 4 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Opexa Therapeutics was the topic in 2 analyst reports since September 28, 2015 according to StockzIntelligence Inc.
03/30/16 01:07 PMOpexa Therapeutics, Inc. (OPXA) Latest Broker Views - Risers & Fallers - Opexa Therapeutics, Inc. (OPXA) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Opexa Therapeutics, Inc. (OPXA). According to the latest broker reports outstanding on Wednesday 30th of March, 0 analysts have a rating of “strong buy”, 4 analysts ...Opexa Therapeutics (OPXA) Short Interest DisclosureThe Sussex PilotHow Analysts Feel About Opexa Therapeutics Inc After Today's Huge Decline?Stock Callerall 3 news articles »
03/26/16 01:08 PMOpexa Therapeutics Enters into Certain Sales Agreement with IFS Securities - Benzinga - Opexa Therapeutics Enters into Certain Sales Agreement with IFS SecuritiesBenzingaOn March 25, 2016, Opexa Therapeutics, Inc. (NASDAQ: OPXA) entered into that certain Sales Agreement (the "Agreement") with IFS Securities, Inc. (doing business as Brinson Patrick, a division of IFS Securities, Inc.) (the "Sales Agent"), under which ...
03/25/16 06:58 PMOpexa Therapeutics Enters into Certain Sales Agreement with IFS Securities - On March 25, 2016, Opexa Therapeutics, Inc. (NASDAQ: OPXA) entered into that certain Sales Agreement (the "Agreement") with IFS Securities, Inc. (doing business as Brinson Patrick, a division of IFS Securities, Inc.) (the "Sales Agent"), under which the Company may sell shares of its common stock from time to time depending upon market demand, with the Sales Agent acting as an agent for sales. Pursuant to the Agreement, the Company may offer and sell the shares in transactions deemed to be an "at-the-market" offering as defined in Rule 415 of the Securities Act of 1933. The Agreement replaces that certain Sales Agreement dated September 6, 2012, as amended on March 5, 2014 (as amended, the "Original Sales Agreement"), between the Company and Meyers Associates, L.P. (doing business as Brinson Patrick, a division of Meyers Associates, L.P.) ...Full story available on Benzinga.com
03/25/16 03:25 PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material De -
03/25/16 01:45 PMHow Many Opexa Therapeutics Inc (NASDAQ:OPXA)'s Analysts Are Bullish? - Clinton Financial - How Many Opexa Therapeutics Inc (NASDAQ:OPXA)'s Analysts Are Bullish?Clinton FinancialOut of 5 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 4 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Opexa Therapeutics was the topic in 2 analyst reports since September 28, 2015 according to StockzIntelligence Inc.
03/19/16 12:04 PMOPEXA THERAPEUTICS, INC. Financials -
03/17/16 01:25 PMOpexa Therapeutics, Inc. :OPXA-US: Earnings Analysis: 2015 By the Numbers -
03/15/16 03:07 PMOPEXA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Fi -
03/15/16 03:06 PMOPEXA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/15/16 03:01 PMOpexa Therapeutics Reports 2015 Year End Financial Results and Provides Corporate Update - [Marketwired] - Opexa Therapeutics, Inc. , a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including Tcelna® for multiple sclerosis and OPX-212 for neuromyelitis optica , ...
03/15/16 06:07 AMQ4 2015 Opexa Therapeutics Inc Earnings Release - After Market Close -
03/14/16 08:00 AMOpexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2015 Financial Results -
About Opexa Therapeutics

Opexa Therapeutics logoOpexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company's T-cell technology. It is engaged in the field of Precision Immunotherapy. The Company's product candidates include Tcelna and OPX-212. Tcelna and OPX-212 are not approved by the United States Food and Drug Administration (FDA) or other global regulatory agencies for marketing. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. In addition to the Company's ongoing clinical development of Tcelna, the Company is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OPXA
  • CUSIP:
Key Metrics:
  • Previous Close: $3.87
  • 50 Day Moving Average: $2.99
  • 200 Day Moving Average: $2.51
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $27.93M
  • Current Quarter EPS Consensus Estimate: $-0.99 EPS
Additional Links:
Opexa Therapeutics (NASDAQ:OPXA) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha